TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam
Study: NCT00015873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Study: NCT01952665

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
Study: NCT00015873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study: NCT00631657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmirtazapine
Description: One esmirtazapine 4.5 mg tablet once a day
Study: NCT01593423

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: plant-based Homestead Food Production
Description: The village model farm will be provided with the necessary inputs to establish their farm including saplings seeds etc.
Study: NCT00631657

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo tablet once a day
Study: NCT01593423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Homestead Food Production plus small pond aquaculture
Description: In the case of the aquaculture arm a pond will be dug if there is not an existing pond and fingerlings and brood stocks will be provided. Hatcheries will be established if there is not one within a reasonable distance of the farms.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: a comparison group
Description: No intervention.
Study: NCT04988711

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hb Oxymeter
Description: Measurement of Hb Oximeter
Study: NCT01617135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-301

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinemet (carbidopa/levodopa)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-301
Study: NCT04254159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Superimposed Neuromuscular Electrical Stimulation
Description: NMES will be applied during each strengthening exercise session. A dual channel NMES stimulation device will be used with biphasic symmetric constant current impulses with a pulse width 300ms, a frequency of 50 Hz and a duty cycle of 10s on and 20s off protocol for 3 days a week for eight weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quadriceps Strengthening
Description: Quadriceps strength training will be done with resistive elastics bands for 3 days a week for eight weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education Program
Description: The aim of patient education is to increase awareness of patients about COPD and develop skills to better manage their disease. The patient education will be performed at least once via face to face interview. Education topics will be covered basic information about COPD, environmental risk factors, monitoring and managing the signs and symptoms of their disease, energy conservation techniques and relaxation positions to reduce dyspnea and usage of a specific inhaler.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education Program
Description: The aim of patient education is to increase awareness of patients about COPD and develop skills to better manage their disease. The patient education will be performed at least once via face to face interview. Education topics will be covered basic information about COPD, environmental risk factors, monitoring and managing the signs and symptoms of their disease, energy conservation techniques and relaxation positions to reduce dyspnea and usage of a specific inhaler.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise Training
Description: Exercise training will be comprised of cardiovascular endurance training with cycle ergometer and lower extremity strength training. The exercises will be done 3 days a week at the clinic under the supervision of physiotherapist. Total duration of exercise training will last for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: Exercise training will be comprised of cardiovascular endurance training with cycle ergometer and lower extremity strength training. The exercises will be done 3 days a week at the clinic under the supervision of physiotherapist. Total duration of exercise training will last for 8 weeks
Study: NCT05945459

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-calorie density formula (1 kcal/ml)
Description: The dose is started from 20ml/kg/day divided into 8 feeds and increased by 20ml/kg/day until the feeding goal is reached (120-150ml/kg/day) during hospitalization. The intervention is then continued after discharge for 3 months (ad libitum).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Standard formula (0.67 kcal/ml)
Description: The dose is started from 20ml/kg/day divided into 8 feeds and increased by 20ml/kg/day until the feeding goal is reached (120-150ml/kg/day) during hospitalization. The intervention is then continued after discharge for 3 months (ad libitum).
Study: NCT00666497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m2/day for 5 days, subcutaneous (SC) injection, Days 1 - 5 of every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m2/day for 5 days, subcutaneous (SC) injection, Days 1 - 5 of every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD0103
Description: 90 mg, oral (PO) administration, 3 times per week for 12 doses, 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD0103
Description: 90 mg, oral (PO) administration, 3 times per week for 10 doses, 28-day cycle
Study: NCT00355342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 mcg BID
Description: Salmeterol xinafoate 50 mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Salmeterol 250/50 mcg BID
Description: Fluticasone propionate/salmeterol xinafoate combination product 250/50mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISKUS inhaler
Description: Each participant received study medication via the DISKUS, for one of two possible treatment groups. Each DISKUS contained 60 doses of study medication. Participants were instructed to administer medication BID (one inhalation in the morning and one inhalation in the evening) approximately 12 hours apart for 156-week treatment period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISKUS inhaler
Description: Each participant received study medication via the DISKUS, for one of two possible treatment groups. Each DISKUS contained 60 doses of study medication. Participants were instructed to administer medication BID (one inhalation in the morning and one inhalation in the evening) approximately 12 hours apart for 156-week treatment period.
Study: NCT02688582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TCI group
Description: Drug: cefepime, Device: Target Controlled Infusion pump connected to Rugloop vII software
Study: NCT03659981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI 7T
Description: The imaging parameters will come from the 7 Tesla Siemens MRI
Study: NCT02078609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGH447
Description: LGH447 in patients with AML or MDS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGH447 + midostaurin
Description: LGH447 + midostaurin in patients with AML
Study: NCT03978585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high tone external muscle stimulation
Description: Participants receive self-administered home based high tone therapy for 8 weeks for 30 minutes daily after device instruction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high tone external muscle stimulation
Description: Participants receive self-administered home based high tone therapy for 8 weeks for 30 minutes daily after device instruction
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam
Study: NCT05454059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodontal Examination
Description: All diagnostic procedures were performed with examination instruments (periodontal probe, dental mirror, x-ray device, etc.). Periodontal clinical index measurements (PI, GI, BOP, PPD, CAL) recorded from all teeth. Routine panoramic radiographs were taken from all patients to determine alveolar bone resorption. Vertical/horizontal bone losses on the radiographs were evaluated and used in the diagnosis of periodontitis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saliva Sample Collection
Description: Saliva samples were collected from all subjects in the morning. Unstimulated saliva from each patient was collected by standard defined spitting method without stimulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva Sample Collection
Description: Saliva samples were collected from all subjects in the morning. Unstimulated saliva from each patient was collected by standard defined spitting method without stimulation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saliva Sample Collection
Description: Saliva samples were collected from all subjects in the morning. Unstimulated saliva from each patient was collected by standard defined spitting method without stimulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva Sample Collection
Description: Saliva samples were collected from all subjects in the morning. Unstimulated saliva from each patient was collected by standard defined spitting method without stimulation.
Study: NCT03978585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical nerve stimulation (TENS) therapy
Description: Participants receive self-administered home based TENS therapy for 8 weeks for 30 minutes daily after device instruction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous electrical nerve stimulation (TENS) therapy
Description: Participants receive self-administered home based TENS therapy for 8 weeks for 30 minutes daily after device instruction
Study: NCT02775734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl-cysteine
Description: N-acetyl-cysteine + Clomiphene citrate + Laparoscopic ovarian drilling

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate
Description: Clomiphene citrate + Laparoscopic ovarian drilling

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate
Description: Clomiphene citrate + Laparoscopic ovarian drilling
Study: NCT01396460

Intervention type: OTHER
Intervention: breakfast (a chicken sandwich with juice)
Description: patients received a breakfast after de initial measurement
Study: NCT05482009

Intervention type: OTHER
Intervention: Traditional Chinese Medicine Treatment Combined with Western Medicine Basic Treatment
Description: The cumulative observation and treatment (including Chinese patent medicine, Chinese medicine decoction, Chinese medicine granule, Chinese medicine injection, and western medicine) were more than 5 months, and the follow-up was 1.5 years.

Intervention type: OTHER
Intervention: Traditional Chinese Medicine Treatment Combined with Western Medicine Basic Treatment
Description: The cumulative observation and treatment (including Chinese patent medicine, Chinese medicine decoction, Chinese medicine granule, Chinese medicine injection, and western medicine) were more than 5 months, and the follow-up was 1.5 years.

Intervention type: OTHER
Intervention: Traditional Chinese Medicine Treatment Combined with Western Medicine Basic Treatment
Description: The cumulative observation and treatment (including Chinese patent medicine, Chinese medicine decoction, Chinese medicine granule, Chinese medicine injection, and western medicine) were more than 5 months, and the follow-up was 1.5 years.
Study: NCT01782664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg GSK2586184
Description: 100 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg GSK2586184
Description: 200 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg GSK2586184
Description: 400 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg GSK2586184
Description: 400 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets to be taken twice daily with food for up to 84 days.
Study: NCT00776347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Dosage: 3mg PO/day for the first 2 weeks and 5mg PO/day for the next 14 weeks Duration: 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Study: NCT04062838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 50
Description: As above
Study: NCT04111679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Participant selected music, applied using noise cancelling headphones
Study: NCT01082965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 5 mg tablets once daily for 7 days and then 10mg on 8th day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT02056912

Intervention type: GENETIC
Group type: OTHER
Intervention: Amplification by PCR and direct sequencing on the entire coding sequence and intron-exons boundaries of the candidate gene

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Perform blood cells and fibroblasts biochemical and immuno-labeled investigations
Description: Performed only in the two index patients enrolled in the sub-study
Study: NCT02570581

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam
Study: NCT05892367

Intervention type: OTHER
Group type: OTHER
Intervention: Transbrachial Access for Interventions
Description: Adding a positioning splint in addition to compression bandage after intervention in order to guarantee immobilization of puncture site

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transbrachial Access for Interventions
Description: Adding a positioning splint in addition to compression bandage after intervention in order to guarantee immobilization of puncture site
Study: NCT01904643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study: NCT02549352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO43204 gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Study: NCT04316078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient engagement platform
Description: 1. Allows patients to receive the action plan as educational videos on demand.~2. Allows patients to report side effects and quality of life via questionnaires and receive immediate targeted education based on the predefined action plan.
Study: NCT03177811

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
Study: NCT06519461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-centered teaching model
Description: The program comprised two parts: (1) Didactic lessons: and (2) Hands-on practice. The didactic lessons were designed to prepare interns' knowledge and skills. The hands-on practice were designed to provide opportunities of family-centered experience to work with caregivers and children.
Study: NCT01174017

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Iodine 125 standard loose brachytherapy seeds
Description: radioactivity 0.4 U per seed, prescribed dose 144 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: AnchorSeed Iodine 125 brachytherapy prostate implant
Description: activity 0.4 U per seed, prescribed dose 144 Gy
Study: NCT03950687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Erythropoiesis Injection (CHO cell)
Description: rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)
Description: rESP is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)
Description: rESP is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
Study: NCT00159575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin / Placebo treatment for 4 months
Description: M: Metformin 2000mg daily- 12-14 weeks of pretreatment + metformin 2000mg daily through conventional IVF ending on the day of pregnancy test; IE. 14 days after embryo transfer. P: Or identical placebo treatment for the same period
Study: NCT01672099

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nutrient enriched product
Description: The intervention in this study consists of the consumption of two nutrient enriched yoghurt products. The participants consume the study products twice a day during 12 weeks, one yoghurt product (250 ml) during breakfast and one yoghurt product (250 ml) during dinner.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: basic dairy product
Description: The intervention in this study consists of the consumption of two basic yoghurt products. The participants consume the basic yoghurt products twice a day during 12 weeks, one yoghurt product (250 ml) during breakfast and one yoghurt product (250 ml) during dinner.
Study: NCT04575818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG4059 oral suspension
Description: GLPG4059 for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG4059 oral suspension
Description: GLPG4059 for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG4059 tablet
Description: GLPG4059 for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG4059 tablet
Description: GLPG4059 for oral administration
Study: NCT00438854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Taken orally once daily. Participants may continue on study treatment as long as there is no disease progression or serious side effects.
Study: NCT02852941

Intervention type: DEVICE
Intervention: CardioScreen 1000
Description: Haemodynamic Measurement System, Medis Impedance cardiography (ICG)

Intervention type: DEVICE
Intervention: CardioScreen 1000
Description: Haemodynamic Measurement System, Medis Impedance cardiography (ICG)

Intervention type: DEVICE
Intervention: Tanita 418- Bioelectrical impedance analysis
Description: The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).

Intervention type: DEVICE
Intervention: Tanita 418- Bioelectrical impedance analysis
Description: The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
Study: NCT02590601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromocriptine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Guideline-driven medical therapy (GDMT)

Intervention type: OTHER
Group type: OTHER
Intervention: Guideline-driven medical therapy (GDMT)
Study: NCT00303446

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride
Description: Dutasteride 0.5 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT04270058

Intervention type: DRUG
Intervention: inotersen
Description: TEGSEDI injection, for subcutaneous use